Back to Investors
Horizons Ventures

Horizons Ventures

Venture Capital

Horizons Ventures acts as the private investment arm for Mr Li Ka-shing, backing prominent technology companies and innovators.

Portfolio

6

companies


Portfolio companies

Owlstone Medical

Owlstone Medical

Owlstone Medical provides breath biopsy technology for early disease detection and precision medicine.

C

CellVoyant

CellVoyant is a biotechnology company developing artificial intelligence platforms to advance novel stem cell therapies.

Synthace

Synthace

Synthace provides a cloud platform that enables life scientists to automate experiments and share insights.

KS

Kuato Studios

Kuato Studios develops educational games and virtual reality software for children.

Curio

Curio

Curio operates a subscription audio platform that provides curated spoken word journalism.

Fidel

Fidel

Fidel provides an API that connects developers to major card networks for real-time payment data.


Team

TC

Teddy Chatjaval

Representative

LinkedIn
PZ

Patrick Zhang

Investor

Patrick is a general partner at Horizons Ventures, focusing on biotech investments. He also holds board observer roles across several life sciences companies, including HistoSonics and Chemify.

LinkedIn

Recent investments

Series D+
£22.0M

Ventura Capital led the Series E round, with participation from Aviva Ventures, Horizons Ventures, and the Gates Foundation, to advance clinical trials and commercialise breath tests.

"Testament to the power of Breath Biopsy is the continued strong support we continue to enjoy from our investors. The funds closed will enable us to progress our business to the next stage, advancing clinical trials and supporting the launch and commercialization of our pipeline of unique breath tests."
— Billy Boyle, co-founder and CEO
Seed
£7.6M

Octopus Ventures led the seed financing, with participation from Horizons Ventures, Verve Ventures, and Air Street Capital, to commercialise live cell imaging technology.

"University spin-outs like CellVoyant are at the heart of the UK’s thriving biotech ecosystem. CellVoyant sets a new standard in precision and reliability for predicting and controlling stem cell behaviour, which will make cell therapies more accessible to those who need them. We are thrilled to invest into a company that is transforming how patients can benefit from life-changing treatments."
— Uzma Choudry, Lead Biotech Investor
Series C
£26.0M

The life sciences software provider raised the capital from Horizons Ventures and Sofinnova Partners to fund commercial growth.

"But to maximize impact, we need to expand access and reach to customers across the globe—at scale. This investment serves as a strong vote of confidence from world-class investors in the biopharmaceutical and innovation technology industries. With their support, we’ll be able to better deploy human and financial capital to help transform scientific dreams into drugs and alternative food sources."
— Guy Levy-Yurista, CEO
Series D+
£42.0M

The oversubscribed financing round will support the commercialisation of proprietary breath biopsy tests.

"We are thrilled to have the support of such highly respected investors as we strive to have a major impact on patient outcomes and the efficient delivery of healthcare resources and are very pleased to now welcome the experience and insight of Horizons’ Patrick Zhang to our Board."
— Billy Boyle, co-founder and CEO
Seed
£4.5M

The London-based educational gaming studio raised the capital from Horizons Ventures to debut its first virtual reality game.

"Virtual reality has progressed significantly over the last decade, but a primary issue stems from the fact it’s a single-person experience. We are incredibly excited to be launching this game as part of our ambition to shift into the VR market."
— Mark Horneff, Managing Director
Series A
£14.6M

The investment round was co-led by Nyca Partners and QED Investors to support international expansion and product development.

"Though the card networks have built extremely robust infrastructure, alternative payment methods are evolving and consumer choice will be driven by value. Our goal at Fidel is to supercharge innovation by empowering everyone in the ecosystem. By making it easy for developers to build on top of the infrastructure, the card networks stay relevant. By removing the barriers to entry for developers, applications can be brought to market more quickly. That drives value back to consumers, who get the same benefits and user experience they are used to receiving with other online services."
— Subrata Dev, Founder and CEO